Journal of Istanbul Faculty of Medicine

SUBMITINFORMATION
EnglishTürkçe

Review


DOI :https://doi.org/10.18017/iuitfd.308493   IUP :https://doi.org/10.18017/iuitfd.308493    Full Text (PDF)

A NEW NATURAL ANTIBIOTIC: TEIXOBACTIN

Gülseren Aktaş

Antibiotic resistance is spreading faster than the introduction of new antimicrobials into clinical practice, causing a public health crisis. Most antibiotics were produced by screening soil microorganisms. This limited resource of cultivable bacteria was overmined by the 1960s. It is reported that uncultured bacteria by in vitro conditions make up approximately 99% of all species in external environments, and are a source of new antibiotics which could not be explored yet. The new technology for growing uncultured organisms by cultivation in situ or by using specific growth factors have been developed. As a result, it is reported that a new antibiotic termed as teixobactin has been discovered in the screening of the new soil bacterium named as Eleftheria terrae. Teixobactin has bactericidal effects in Grampositive bacteria inhibiting cell wall synthesis by binding to lipid II which is a a highly conserved precursor of peptidoglycan and lipid III which is a precursor of cell wall teichoic acid. It has been tested in two animal infection models: blood infections of methicillin-resistant Staphylococcus aureus and lung infections of Streptococcus pneumoniae. As a result, all animals were treated successfully and none developed resistance. If teixobactin is approved, it will be the first of a new class of antibiotics.

Keywords: Antimicrobial drug resistance, gram positive bacteria
DOI :https://doi.org/10.18017/iuitfd.308493   IUP :https://doi.org/10.18017/iuitfd.308493    Full Text (PDF)

YENİ BİR DOĞAL ANTİBİYOTİK: “TEİKSOBAKTİN”

Gülseren Aktaş

Ciddi sağlık problemlerine sebep olan antibiyotik direnci, etkili yeni antimikrobial maddelerin klinik kullanıma girmesinden çok daha hızlı bir şekilde ortaya çıkmakta ve yayılmaktadır. Antibiyotiklerin çoğu toprak mikroorganizmalarından elde edilmişlerdir. Bu, kültürü yapılabilen sınırlı sayıdaki toprak bakterilerileri, 1960’lı yıllara kadar yoğun olarak antibiyotik üretiminde kullanılmışlardır. Doğal ortamlarda yaşayan mikroorganizmaların yaklaşık olarak % 99’unun in vitro şartlarda kültürü yapılamamış bakteriler olduğu ve bunların henüz keşfedilememiş yeni antibiyotiklerin kaynağı olduğu bildirilmiştir.

Kültürü yapılamamış mikorganizmaları üretmek için doğal ortamlarının veya özel üreme faktörlerinin kullanıldığı yeni bir teknoloji geliştirilmiştir. Bu teknoloji ile henüz kültürü yapılamamış Eleftheria terrae olarak isimlendirilen yeni bir toprak bakterisinden, “teiksobaktin” olarak isimlendirilen yeni bir antibiyotiğin elde edildiği bildirilmiştir. “Teiksobaktin”, Gram-pozitif bakterilerde peptidoglikanın öncü maddesi olan ve çok iyi korunmuş lipid II’ye ve hücre duvarındaki teikoik asidin öncü maddesi olan lipid III’e bağlanır. Böylece, hücre duvarı sentezini engelleyerek bakterisit etki gösterir. “Teiksobaktin”, metisiline dirençli Staphylococcus aureus ile kanda ve Streptococcus pneumoniae ile akciğerlerde enfeksiyon oluşturulmuş iki hayvan modeli üzerinde denenmiştir. Sonuçta, tüm denenen hayvanlar başarılı bir şekilde tedavi edilmişler ve hiçbirinde direnç gelişimi gözlenmemiştir. Eğer onaylanırsa, “teiksobaktin” yeni bir antibiyotik sınıfının ilk üyesi olacaktır. 

Keywords: Antimikrobiyal ilaç direnci, Gram-pozitif bakteriler, teiksobaktin

PDF View

References

  • 1- Alekshun MN, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. Cell 2007; 128(6): 1037-50. google scholar
  • 2- Lewis K. Antibiotics: Recover the lost art of drug discovery. Nature 2012; 485(7399): 439-40. google scholar
  • 3- Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P et al. Tackling antibiotic resistance. Nat Rev Microbiol 2011; 9(12): 894-6. google scholar
  • 4- Livermore DM. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother 2011; 66(9): 1941-4. google scholar
  • 5- Lewis K. Platforms for antibiotic discovery. Nat Rev Drug Discov 2013; 12(5): 371-87. google scholar
  • 6- Lewis K, Epstein S, D'Onofrio A, Ling LL. Uncultured microorganisms as a source of secondary metabolites. J Antibiot (Tokyo) 2010; 63(8): 468-76. google scholar
  • 7- Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP et al. A new antibiotic kills pathogens without detectable resistance. Nature 2015; 517(7535): 455-9. google scholar
  • 8- D'Onofrio A, Crawford JM, Stewart EJ, Witt K, Gavrish E, Epstein S et al. Siderophores from neighboring organisms promote the growth of uncultured bacteria. Chem Biol 2010; 17(3): 254-64. google scholar
  • 9- Laura J. V. Piddock. Teixobactin, the first of a new class of antibiotics discovered by iChip technology? J Antimicrob Chemother 2015; 70(10): 2679–80. google scholar
  • 10-Bryskier A, Dini C. Peptidoglycan synthesis inhibitors. In: Bryskier A (ed). Antimicrobial Agents. ASM Press. Washington DC, USA, 2005;.377-400. google scholar
  • 11-D'Elia MA, Pereira MP, Chung YS, Zhao W, Chau A, Kenney TJ et al. Lesions in teichoic acid biosynthesis in Staphylococcus aureus lead to a lethal gain of function in the otherwise dispensable pathway. J Bacteriol 2006; 188(12): 4183-9. google scholar
  • 12-Kahne D, Leimkuhler C, Lu W, Walsh C. Glycopeptide and lipoglycopeptide antibiotics. Chem Rev 2005; 105(2): 425-48. google scholar
  • 13-Schneider T, Sahl HG. An oldie but a goodie - cell wall biosynthesis as antibiotic target pathway. Int J Med Microbiol 2010; 300(2-3): 161-9. google scholar
  • 14-Bryskier A, Veyssier P. Glycopeptides and Lipoglycopeptides. In: Bryskier A, ed. Antimicrobial Agents. ASM Press. Washington DC, USA 2005; p.880-905. google scholar
  • 15-Patel R. Enterococcal-type glycopeptide resistance genes in non-enterococcal organisms. FEMS Microbiol Lett. 2000; 185(1): 1-7. google scholar
  • 16-Sancak B. Staphylococcus aureus and antibiotic resistance. Mikrobiyol Bul. 2011; 45(3): 565-76. google scholar
  • 17-Marshall CG, Broadhead G, Leskiw BK, Wright GD. D-Ala-D-Ala ligases from glycopeptide antibiotic-producing organisms are highly homologous to the enterococcal vancomycinresistance ligases VanA and VanB. Proc Natl Acad Sci U S A 1997; 94(12): 6480-3. google scholar
  • 18-Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B et al. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem 2001; 276(3): 1772-9. google scholar
  • 19-D'Costa VM, Griffiths E, Wright GD. Expanding the soil antibiotic resistome: exploring environmental diversity. Curr Opin Microbiol 2007; 10(5): 481-9. google scholar
  • 20-D'Costa VM, McGrann KM, Hughes DW, Wright GD. Sampling the antibiotic resistome. Science 2006; 311(5759): 374-7. google scholar
  • 21-Forsberg KJ, Patel S, Gibson MK, Lauber CL, Knight R, Fierer N, et al. Bacterial phylogeny structures soil resistomes across habitats. Nature 2014; 509(7502): 612-6. google scholar
  • 22-Pickup RW, Rhodes G. Mechanisms for resistance in soil. Science 2006; 312(5773): 529. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Aktaş, G. (2016). A NEW NATURAL ANTIBIOTIC: TEIXOBACTIN. Journal of Istanbul Faculty of Medicine, 79(4), 163-168. https://doi.org/https://doi.org/10.18017/iuitfd.308493


AMA

Aktaş G. A NEW NATURAL ANTIBIOTIC: TEIXOBACTIN. Journal of Istanbul Faculty of Medicine. 2016;79(4):163-168. https://doi.org/https://doi.org/10.18017/iuitfd.308493


ABNT

Aktaş, G. A NEW NATURAL ANTIBIOTIC: TEIXOBACTIN. Journal of Istanbul Faculty of Medicine, [Publisher Location], v. 79, n. 4, p. 163-168, 2016.


Chicago: Author-Date Style

Aktaş, Gülseren,. 2016. “A NEW NATURAL ANTIBIOTIC: TEIXOBACTIN.” Journal of Istanbul Faculty of Medicine 79, no. 4: 163-168. https://doi.org/https://doi.org/10.18017/iuitfd.308493


Chicago: Humanities Style

Aktaş, Gülseren,. “A NEW NATURAL ANTIBIOTIC: TEIXOBACTIN.” Journal of Istanbul Faculty of Medicine 79, no. 4 (Aug. 2025): 163-168. https://doi.org/https://doi.org/10.18017/iuitfd.308493


Harvard: Australian Style

Aktaş, G 2016, 'A NEW NATURAL ANTIBIOTIC: TEIXOBACTIN', Journal of Istanbul Faculty of Medicine, vol. 79, no. 4, pp. 163-168, viewed 29 Aug. 2025, https://doi.org/https://doi.org/10.18017/iuitfd.308493


Harvard: Author-Date Style

Aktaş, G. (2016) ‘A NEW NATURAL ANTIBIOTIC: TEIXOBACTIN’, Journal of Istanbul Faculty of Medicine, 79(4), pp. 163-168. https://doi.org/https://doi.org/10.18017/iuitfd.308493 (29 Aug. 2025).


MLA

Aktaş, Gülseren,. “A NEW NATURAL ANTIBIOTIC: TEIXOBACTIN.” Journal of Istanbul Faculty of Medicine, vol. 79, no. 4, 2016, pp. 163-168. [Database Container], https://doi.org/https://doi.org/10.18017/iuitfd.308493


Vancouver

Aktaş G. A NEW NATURAL ANTIBIOTIC: TEIXOBACTIN. Journal of Istanbul Faculty of Medicine [Internet]. 29 Aug. 2025 [cited 29 Aug. 2025];79(4):163-168. Available from: https://doi.org/https://doi.org/10.18017/iuitfd.308493 doi: https://doi.org/10.18017/iuitfd.308493


ISNAD

Aktaş, Gülseren. “A NEW NATURAL ANTIBIOTIC: TEIXOBACTIN”. Journal of Istanbul Faculty of Medicine 79/4 (Aug. 2025): 163-168. https://doi.org/https://doi.org/10.18017/iuitfd.308493



TIMELINE



SHARE



Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.